These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

260 related items for PubMed ID: 23772754

  • 1. A novel RT-qPCR assay for quantification of the MLL-MLLT3 fusion transcript in acute myeloid leukaemia.
    Abildgaard L, Ommen HB, Lausen B, Hasle H, Nyvold CG.
    Eur J Haematol; 2013 Nov; 91(5):394-8. PubMed ID: 23772754
    [Abstract] [Full Text] [Related]

  • 2. Monitoring of minimal residual disease (MRD) by real-time quantitative reverse transcription PCR (RQ-RT-PCR) in childhood acute myeloid leukemia with AML1/ETO rearrangement.
    Viehmann S, Teigler-Schlegel A, Bruch J, Langebrake C, Reinhardt D, Harbott J.
    Leukemia; 2003 Jun; 17(6):1130-6. PubMed ID: 12764380
    [Abstract] [Full Text] [Related]

  • 3. Quantitative RT-PCR analysis of the MOZ-CBP fusion transcript in therapy-related acute myeloid leukemia with t(8;16)(p11;p13).
    Fujiki A, Imamura T, Furutani A, Hatano W, Asai D, Hirashima Y, Miyachi M, Tamura S, Tsuchiya K, Iehara T, Ishida H, Yoshihara T, Hosoi H.
    J Pediatr Hematol Oncol; 2012 Jul; 34(5):402-5. PubMed ID: 22278196
    [Abstract] [Full Text] [Related]

  • 4. Detection and treatment of molecular relapse in acute myeloid leukemia with RUNX1 (AML1), CBFB, or MLL gene translocations: frequent quantitative monitoring of molecular markers in different compartments and correlation with WT1 gene expression.
    Doubek M, Palasek I, Pospisil Z, Borsky M, Klabusay M, Brychtova Y, Jurcek T, Jeziskova I, Krejci M, Dvorakova D, Mayer J.
    Exp Hematol; 2009 Jun; 37(6):659-72. PubMed ID: 19463768
    [Abstract] [Full Text] [Related]

  • 5. The prognostic value of MLL-AF9 detection in patients with t(9;11)(p22;q23)-positive acute myeloid leukemia.
    Scholl C, Schlenk RF, Eiwen K, Döhner H, Fröhling S, Döhner K, AML Study Group.
    Haematologica; 2005 Dec; 90(12):1626-34. PubMed ID: 16330435
    [Abstract] [Full Text] [Related]

  • 6. Development of a real-time RT-PCR assay for the quantification of the most frequent MLL/AF9 fusion types resulting from translocation t(9;11)(p22;q23) in acute myeloid leukemia.
    Scholl C, Breitinger H, Schlenk RF, Döhner H, Fröhling S, Döhner K, AML Study Group Ulm.
    Genes Chromosomes Cancer; 2003 Nov; 38(3):274-80. PubMed ID: 14506704
    [Abstract] [Full Text] [Related]

  • 7. Quantitative nested reverse transcriptase PCR vs. real-time PCR for measuring AML1/ETO (MTG8) transcripts.
    Takenokuchi M, Yasuda C, Takeuchi K, Nakamachi Y, Mukai M, Kondo S, Kumagai S, Saigo K, Murayama T, Koizumi T, Tatsumi E.
    Clin Lab Haematol; 2004 Apr; 26(2):107-14. PubMed ID: 15053804
    [Abstract] [Full Text] [Related]

  • 8. Fusion gene transcripts and Ig/TCR gene rearrangements are complementary but infrequent targets for PCR-based detection of minimal residual disease in acute myeloid leukemia.
    Boeckx N, Willemse MJ, Szczepanski T, van der Velden VH, Langerak AW, Vandekerckhove P, van Dongen JJ.
    Leukemia; 2002 Mar; 16(3):368-75. PubMed ID: 11896540
    [Abstract] [Full Text] [Related]

  • 9. Real-time quantitative polymerase chain reaction detection of minimal residual disease by standardized WT1 assay to enhance risk stratification in acute myeloid leukemia: a European LeukemiaNet study.
    Cilloni D, Renneville A, Hermitte F, Hills RK, Daly S, Jovanovic JV, Gottardi E, Fava M, Schnittger S, Weiss T, Izzo B, Nomdedeu J, van der Heijden A, van der Reijden BA, Jansen JH, van der Velden VH, Ommen H, Preudhomme C, Saglio G, Grimwade D.
    J Clin Oncol; 2009 Nov 01; 27(31):5195-201. PubMed ID: 19752335
    [Abstract] [Full Text] [Related]

  • 10. Prognostic value of minimal residual disease quantification by real-time reverse transcriptase polymerase chain reaction in patients with core binding factor leukemias.
    Krauter J, Gorlich K, Ottmann O, Lubbert M, Dohner H, Heit W, Kanz L, Ganser A, Heil G.
    J Clin Oncol; 2003 Dec 01; 21(23):4413-22. PubMed ID: 14645432
    [Abstract] [Full Text] [Related]

  • 11. Minimal residual disease monitoring by quantitative RT-PCR in core binding factor AML allows risk stratification and predicts relapse: results of the United Kingdom MRC AML-15 trial.
    Yin JA, O'Brien MA, Hills RK, Daly SB, Wheatley K, Burnett AK.
    Blood; 2012 Oct 04; 120(14):2826-35. PubMed ID: 22875911
    [Abstract] [Full Text] [Related]

  • 12. [Clinical and experimental studies of childhood acute myeloid leukemia with 11q23/MLL rearrangements].
    He YX, Xue YQ, Wang HY, Shao XJ, Pan JL, Xu J, Yang NC, Ji ZH, Huang YP, Hu SY.
    Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2012 Dec 04; 29(6):677-82. PubMed ID: 23225048
    [Abstract] [Full Text] [Related]

  • 13. Minimal residual disease in acute myeloid leukaemia.
    Liu Yin JA.
    Best Pract Res Clin Haematol; 2002 Mar 04; 15(1):119-35. PubMed ID: 11987920
    [Abstract] [Full Text] [Related]

  • 14. Minimal residual disease monitoring in t(8;21) acute myeloid leukemia based on RUNX1-RUNX1T1 fusion quantification on genomic DNA.
    Duployez N, Nibourel O, Marceau-Renaut A, Willekens C, Helevaut N, Caillault A, Villenet C, Celli-Lebras K, Boissel N, Jourdan E, Dombret H, Figeac M, Preudhomme C, Renneville A.
    Am J Hematol; 2014 Jun 04; 89(6):610-5. PubMed ID: 24616160
    [Abstract] [Full Text] [Related]

  • 15. Measurable residual disease assessment by qPCR in peripheral blood is an informative tool for disease surveillance in childhood acute myeloid leukaemia.
    Juul-Dam KL, Ommen HB, Nyvold CG, Walter C, Vålerhaugen H, Kairisto V, Abrahamsson J, Alm SJ, Jahnukainen K, Lausen B, Reinhardt D, Zeller B, von Neuhoff N, Fogelstrand L, Hasle H.
    Br J Haematol; 2020 Jul 04; 190(2):198-208. PubMed ID: 32175599
    [Abstract] [Full Text] [Related]

  • 16. Monitoring the AML1/ETO fusion transcript to predict outcome in childhood acute myeloid leukemia.
    Zhang L, Cao Z, Ruan M, Zeng Q, Zhao L, Li Q, Zou Y, Wang J, Zhu X.
    Pediatr Blood Cancer; 2014 Oct 04; 61(10):1761-6. PubMed ID: 24920269
    [Abstract] [Full Text] [Related]

  • 17. AML1/ETO fusion mRNA can be detected in remission blood samples of all patients with t(8;21) acute myeloid leukemia after chemotherapy or autologous bone marrow transplantation.
    Kusec R, Laczika K, Knöbl P, Friedl J, Greinix H, Kahls P, Linkesch W, Schwarzinger I, Mitterbauer G, Purtscher B.
    Leukemia; 1994 May 04; 8(5):735-9. PubMed ID: 7514242
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Relevance of presenting white blood cell count and kinetics of molecular remission in the prognosis of acute myeloid leukemia with CBFbeta/MYH11 rearrangement.
    Martín G, Barragán E, Bolufer P, Chillón C, García-Sanz R, Gómez T, Brunet S, González M, Sanz MA.
    Haematologica; 2000 Jul 04; 85(7):699-703. PubMed ID: 10897121
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.